Who We Are

KELIX bio is a specialty generic business focused on Emerging Markets and designed to compete through innovation and cost leadership. KELIX bio aims to develop and commercialize affordable specialty products in jurisdictions historically deprived of access to such medications. KELIX bio’s investors include Development Partners International (“DPI”), British International Investment (“BII”), the UK’s publicly owned impact investor, and the European Bank for Reconstruction and Development (“EBRD”).

Our Shareholders

  • British International Investment (BII). Learn More
  • Development Partners International (DPI). Learn More
  • European Bank for Reconstruction and Development (EBRD). Learn More

Our Board

Name Role Representation
Hocine Sidi Said Director Kelix bio
Sofiane Lahmar Director Development Partners International
Samir Abhyankar Director British International Investment
Florence Bachelard-Bakal Director European Bank for Reconstruction and Development